News headlines about Applied Genetic Technologies (NASDAQ:AGTC) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.4391373893523 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

AGTC has been the topic of a number of recent analyst reports. ValuEngine cut Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Applied Genetic Technologies in a research note on Wednesday, November 8th. BMO Capital Markets reiterated an “outperform” rating and set a $7.00 target price (down from $14.00) on shares of Applied Genetic Technologies in a research note on Thursday, September 14th. Zacks Investment Research cut Applied Genetic Technologies from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 31st. Finally, Cantor Fitzgerald set a $9.00 target price on Applied Genetic Technologies and gave the stock a “hold” rating in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.17.

Applied Genetic Technologies (AGTC) traded up $0.05 during midday trading on Friday, hitting $3.63. The stock had a trading volume of 162,000 shares, compared to its average volume of 163,071. Applied Genetic Technologies has a 12 month low of $3.25 and a 12 month high of $10.15.

Applied Genetic Technologies (NASDAQ:AGTC) last announced its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.40). Applied Genetic Technologies had a negative return on equity of 2.86% and a negative net margin of 8.78%. The firm had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $12.39 million. During the same period last year, the business posted $0.15 EPS. The company’s revenue was down 31.4% compared to the same quarter last year. research analysts predict that Applied Genetic Technologies will post -1.14 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Applied Genetic Technologies (AGTC) Earning Somewhat Favorable News Coverage, Study Finds” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/15/applied-genetic-technologies-agtc-earning-somewhat-favorable-news-coverage-study-finds.html.

About Applied Genetic Technologies

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Insider Buying and Selling by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Stock Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related stocks with our FREE daily email newsletter.